Complement as a target in COVID-19?

Antonio M. Risitano(University of Naples Federico II), Dimitrios C. Mastellos(National Centre of Scientific Research "Demokritos"), Markus Huber‐Lang(University Hospital Ulm), Despina Yancopoulou, Cecília Garlanda(Humanitas University), Fabio Ciceri(Vita-Salute San Raffaele University), John D. Lambris(University of Pennsylvania)
Nature reviews. Immunology
April 23, 2020
10.1038/s41577-020-0320-7
Cited by 513Open Access
Full Text

Abstract

Related Papers

Clinical Characteristics of Coronavirus Disease 2019 in China
Wei‐jie Guan, Zhengyi Ni, Yu Hu et al.|New England Journal of Medicine|2020|31.1k
Coronavirus infections and immune responses
Geng Li, Yaohua Fan, Yanni Lai et al.|Journal of Medical Virology|2020|2k
Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis
Lisa E. Gralinski, Timothy P. Sheahan, Thomas E. Morrison et al.|mBio|2018|698
Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation
Ting Gao, Mingdong Hu, Xiaopeng Zhang et al.|medRxiv|2020|363
Clinical promise of next-generation complement therapeutics
Dimitrios C. Mastellos, Daniel Ricklin, John D. Lambris|Nature Reviews Drug Discovery|2019|342